Insurmountable AT 1 receptor antagonism: the need for different antagonist binding states of the receptor

By Vauquelin G.   Fierens F.   Verheijen I.   Vanderheyden P.  

Trends in Pharmacological Sciences, Vol. 22, Iss. 7, 2001-07 ,pp. : 343-344

Elsevier

Access to resources Recommend Favorite

Effects of the insurmountable angiotensin AT 1 receptor antagonist candesartan and the surmountable antagonist losartan on ischemia/reperfusion injury in rat hearts

By Wang Q.-D.   Sjoquist P.-O.  

European Journal of Pharmacology, Vol. 380, Iss. 1, 1999-09 ,pp. : 13-21

Elsevier

Access to resources Recommend Favorite

The Role of Angiotensin II Type 1 Receptor Antagonists in Elderly Patients with Hypertension

By Thomas G. Neil  

Drugs & Aging, Vol. 23, Iss. 2, 2006-01 ,pp. : 131-155

Adis International

Access to resources Recommend Favorite

Binding of the antagonist [ 3 H]candesartan to angiotensin II AT 1 receptor-tranfected Chinese hamster ovary cells

By Fierens F.   Vanderheyden P.M.L.   De Backer J.-P.   Vauquelin G.  

European Journal of Pharmacology, Vol. 367, Iss. 2, 1999-02 ,pp. : 413-422

Elsevier

Access to resources Recommend Favorite

Valsartan: a novel angiotensin Type 1 receptor antagonist

By Thürmann P.A.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 2, 2000-01 ,pp. : 337-350

Informa Healthcare

Access to resources Recommend Favorite